

Developing Countries Vaccine Manufacturers Network

- munut


Annual General Meeting 19 to 21 September 2023 Cape Town South Africa

Sushant Sahastrabuddhe Deputy Director General (Acting) Clinical, Assessment, Regulatory, Evaluation (CARE)

IVI: Who we are, where we work, and what we do!

Epi. Surveillance (\mathbf{A}) Discover Deliver Develop **IVI is an UN-chartered** Protocol dev. incl. definition of Critical assay development & Material production, Field-based data optimizatio endpoint, bio investigation, & collection incl. costing & willingness to pay test & release for database & Clinical Method validation according to ICH toxicology studies re-Clin international organization Samples guideline Prevalence & incidence est, of Study & Epidemiolog Evaluation Observationa Protocol dev Health Clinical sample evaluation in GCLP lab Study Support Data for decision on vaccine CMO/CRO Global/country analyses incl. invest., dedicated to accelerating vaccine Study Tech Transfer Candidates & process transfer to CMOs introduction & stability plan d budget impact, cost-Site preparedness for Ph.3 trial & effectiveness study Scalable & optimized Process scale-up & ensuring of effectiveness, demand **R&D** for global health & disease burden AMR assessment & public AME processes for candidate Mfg. Support commercial-scale mfg. & vaccine candidate supply Monito database creation Process 8 IPDP & CDP development Mass vaccination campaign nalytical Policy & Advocacy Research Analytical methods for Vaccine intro through health Dev. Clinical Dev. & accine Impa Clinical trial implementation & qual. testing Vaccine impact & disease risk mapping & Effective Regulatory authorities management in HIC & LMIC Support Study Real-life vaccine performance In vivo animal studies Regulatory affairs consultation etc assessme Invasive Non-typhoidal Salmonella (INTS) Human Papilloma Virus (HPV) Typhoid Cholera INTS Paratyphoid A Group A strep Zika MERS-CoV Hepatitis E SETSV Hantavirus Chikungunya Schistosomiasis Cholera . COVID-19 ... is to discover, develop and deliver safe, effective Shigella Pulmonary COVID-19 RSV Our mission Hepatitis A. B Syndrome (HPS) Typhoid : GAS and affordable vaccines to enable the world's most Tuberculo COVID-19 Shigella HAdV-55 Lassa fever Cholera AMR vulnerable people to have full, productive lives COVID-19 MERS Micro-needle array (MAP) Hep-B 0-... is to expand our global presence and expand our collaborative 8 Next step partnerships and innovative capabilities yphoid Conjugation Vaccine <u>Partnership</u>: Technology transfer ... we can achieve our VISION of developing countries free Stage: Licensed for export by Together Korean Ministry of Food and of suffering from infectious disease Drug Safety Under WHO PO radentification process Partnership: IVI re-formulated & redeveloped process to meet Europe Regional Office WHO standards. Stockholm Sweder <u>Stage</u>: Licensed in Vietnam 50 1 Sep 2022 (for domestic use) 20 Headquarters **Dengue Vaccine** Seoul, South Korea Partnership: IVI re-formulated **Country Office** 1997 Vienna, Austria US NIH Dengue vaccine & 2 Nov 22 Technology transfer Oral Cholera Vaccine oral Cholera Vacci 20 Partnership: Technology Partnership: Technology transfer transfer engue Vaccine <u>Stage:</u> Registered in Bangladesh Stage: Tech Transfer Partnership: IVI re-AMSON VACCINES & PHARMA (PVT) ITD ongoing since 2019 formulated US NIH yphoid Conjugation Vaccine bioco **Typhoid Coniugation Vaccine** Dengue vaccine & Partnership: Technology Technology transfer B Oral Cholera Vaccine Partnership: IVI-facilitated transfer SHANTHA Oral Cholera Vaccir ACCELERATING VACI Stage: PH III data OVA Partnership: technology transfer 2008 * Vi-PS Stage: BLA submitted to BPOM Partnership: Technology 2 Collab ating Cente Technology transfer from Bharat Biotech (National Agency of Drug and review transfer In Ghana, Madagascar, Food Control of Indonesia) Stage: Tech Transfer Stage: Licensed for domestic use Stage: Licensed in India (Feb and Ethiopi ongoing since 2023 by Drug Regulatory Authority 2009) WHO pregualified Sep Other (COVID-19, of Pakist **Q** Cholera Ochikungunya, AMR, etc). 2011 **V**Typhoid

IVI Vaccines Bring Affordable Innovation to Global Health



2

IVI's model of market access:

- Affordability (global access requirements)
- Work with global, regional and local entities
- Facilitation with data generation (surveillance, economics, impact assessment, clinical)
- Advocacy and coordination: GTFCC, PDVI, DVI
- Collaboration and technology transfer for local access
- Innovative technologies to reach the last-mile (MAP)